SARS-CoV-2 Omicron sub-variant Neutralization following a primary vaccine series of NVX-CoV2373 and BNT162b2 monovalent booster vaccine
Abstract. We evaluated the immunologic response to a novel vaccine regimen that included two doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfiz